Ordaōs is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods.
External link for Ordaos Bio
434 w 33rd st
New York, NEW YORK 10001, US
228 Park Ave S
60684
New York, NY 10003-1502, US
CEO @ Ordaos Bio. Intelligent Drug Design Factory Builder. Harvard Biotech. Stanford AI/ML. MIT Sloan EDP.
Powerful innovations in #Biotech are helping breathe new life into people, products, and the planet. Ordaos Bio's work is featured in Deloitte's new #xTech Futures: BioTech report! https://deloi.tt/3KPxOgb
CEO @ Ordaos Bio. Intelligent Drug Design Factory Builder. Harvard Biotech. Stanford AI/ML. MIT Sloan EDP.
So grateful to have represented Ordaos Bio at BIO Korea this month in Seoul! Witnessing Korea's commitment to the tech bio revolution was truly inspiring. The collaboration between Johnson & Johnson Innovation and the Republic of Korea's Ministry of Health & Welfare is set to drive growth and globalization in this field. Excited for Ordaos to be part of JLABS Korea! Huge thanks to Sharon Chan, Melinda Richter, Jesse Hwang, Tingting Zhang-Kharas, PhD, and everyone involved for this incredible opportunity. Ordaos continues accelerating the reduction of disease burden globally with groundbreaking technology. #BIOKorea #TechBio #Innovation #Ordaos #JLabsKorea #JohnsonandJohnsonInnovation 🌏💉🔬
Attending BIO Partnering at JPM Week? Click below to send Ordaos a meeting request in the BIO partnering system! #JPM2024 https://hubs.li/Q02f932V0 We look forward to seeing you next week in San Francisco.
Our CEO, David Longo, was a guest speaker on Daniel Levine's podcast, The BIO Report, to discuss Ordaōs' groundbreaking work in drug development, the advantages mini-proteins have over traditional antibodies, and how our generative AI platform is leading an industry-wide shift in biotech from drug discovery to drug design. Listen in to learn more: https://hubs.li/Q025Hs9H0
Ordaos is #hiring! We're looking for a Backend Engineer II to be a part of our ongoing mission to create bespoke mini-proteins to enable ground-breaking therapeutics. 🚀 Apply here: https://lnkd.in/ednhuXE3 #biotechjobs #techjobs
Our CEO, David Longo, and CSO, Ziwei Liang, had the great opportunity to talk with Genetic Engineering & Biotechnology News on the exciting opening of our Ordaōs lab space in New York, how it will support our R&D efforts & capabilities in mini-protein design, and how the fusion of AI in biotech is re-shaping the drug discovery process as we know it. Read the article here: https://hubs.li/Q01-R2cl0
🌟 Celebrating Sahil Arora: AI Scientist II at Ordaos 🌟 Join us in recognizing the remarkable contributions of Sahil, our outstanding AI Scientist II since October 2022. When prompted, Sahil indicated that what excites him most about working at Ordaos is: "working on a new modality with mini-proteins that can be used in a wide variety of treatments. I am especially excited that at Ordaos we can design miniproteins de novo with reinforcement learning and that I can use new tools in generative AI and geometric deep learning to further optimize their functionality." We're very lucky and grateful to have Sahil on the Ordaos team! #EmployeeSpotlight #toptalent #Ordaos #AI